Illuminaの発行済株式数
Illuminaの発行済株式数は何ですか。
Illumina, Inc.の発行済株式数は147.000Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
LSEのセクタMiscellaneousにおける発行済株式数の企業と比べるIllumina
Illuminaは何をしますか。
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Illuminaと類似の発行済株式数
- CapMan Oyjの発行済株式数は146.896Mです。
- Security and Intelligence Services (India)の発行済株式数は146.902Mです。
- Resmedの発行済株式数は146.932Mです。
- Sparton Resourcesの発行済株式数は146.942Mです。
- The Great Eastern Shippingの発行済株式数は146.966Mです。
- The Great Eastern Shippingの発行済株式数は146.966Mです。
- Illuminaの発行済株式数は147.000Mです。
- Imperial Miningの発行済株式数は147.006Mです。
- Imperial Miningの発行済株式数は147.006Mです。
- E2Goldの発行済株式数は147.071Mです。
- Xebec Adsorptionの発行済株式数は147.087Mです。
- Max Ventures and Industriesの発行済株式数は147.094Mです。
- Acanthe Developpementの発行済株式数は147.125Mです。